Fast boat to China
Abbisko aims to be first to market in China with ‘me better’ cancer compounds
Abbisko Therapeutics aims to be first-to-market for common cancer indications in China with small molecules against clinically validated targets that are more potent than competing agents in development outside the country.
Abbisko is focusing first on developing therapies against clinically validated targets for indications, like hepatocellular carcinoma (HCC), that are prevalent in China.
“In the beginning, we will work on validated targets that still